CAESAREA, Israel, Dec. 10, 2025 /PRNewswire/ — Nitinotes Ltd., an early commercial stage medical technology company developing fully automated endoluminal suturing solutions for obesity treatment, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) EASE™ Clinical Trial evaluating the EndoZip™ Automated Suturing System for endoscopic sleeve gastroplasty (ESG). The procedure was performed at Lenox Hill Hospital | Northwell Health in New York, NY, the trial’s first activated U.S. site.
Nitinotes Announces First Patient Treated in Pivotal EASE™ Clinical Trial Evaluating the EndoZip™ Automated Suturing System for ESG
